Pharmacokinetics and Oral Bioavailability of Paclitaxel Microemulsion in Rats |
Hur, Hye-Jung
(College of Pharmacy, Ewha Womans University)
Park, Joon-Hee (College of Pharmacy, Ewha Womans University) Kim, Seo-Young (College of Pharmacy, Ewha Womans University) Yang, Hyun-Kyoung (College of Pharmacy, Ewha Womans University) Kim, Ji-Hyeon (College of Pharmacy, Ewha Womans University) Ryu, Jae-Kook (Department of Pharmaceutical Research and Development, Hanmi Pharmaceutical Co. LTD.) Woo, Jong-Soo (College of Pharmacy, Yeungnam University) Lee, Byung-Koo (College of Pharmacy, Ewha Womans University) Lee, Hwa-Jeong (College of Pharmacy, Ewha Womans University) |
1 | J.S. Woo, C.H. Lee, C.K. Shim and S.J. Hwang, Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031, Pharm. Res., 20, 24-30 (2003) DOI ScienceOn |
2 | G.J. Fetterly and R.M. Straubinger, Pharmacokinetics of paclitaxel-containing liposomes in rats, AAPS PharmSci., 5, E32, 1-11 (2003) |
3 | P.P. Constantinides, J.P. Scalart, C. Lancaster, J. Marcello, G. Marks, H. Ellens and P.L. Smith, Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycetides, Pharm. Res., 11, 1386-1390 (1994) |
4 | Y. Dong and S.S. Feng, Poly (D.L-lactide-o-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, 6068-6076 (2005) DOI ScienceOn |
5 | P.K. Ghosh, R.J. Majithiya, M.L. Umrethia and R.S.R. Murthy, Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability, AAPS PharmSciTech., 7, Article 77, E1-E6 (2006) |
6 | B. Matuszewska, L. Hettrick, J. Bondi and D. Storey, Comparative bioavailability of L-683, 453, a 5a-reductase inhibitor, from a self-emulsifying drug delivery system in beagle dogs, Int. J. Pharm., 136, 147-154 (1996) DOI ScienceOn |
7 | M.M. Malingre, J.H.M. Schellens, O. Van Tellingen, M. Ouwehand, H.A. Bardelmeijer, H. Rosing, F.J. Koopman, S.E. Jansen, M.E. Schot, W.W. Ten Bokkel Huinink and J.H. Beijnen, The co-solvent cremophor EL limits absorption of orally administered paclitaxel in cancer patients, Br. J. Cancer, 85, 1472-1477 (2001) DOI ScienceOn |
8 | F. Kees, M. Bucher, F. Schweda, H. Gschaidmeier, J. Burhenne, G. Mikus and L. Faerber, Comparative bioavailability of the microemulsion formulation of cyclosporine with a generic dispersion formulation in young healthy male volunteers, Ther. Drugmonit, 28, 312-320 (2006) DOI ScienceOn |
9 | N. Shah, M. Carvajal, C. Patel, M. Infeld and A. Malick, Selfemulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs, Int. J. Pharm., 106, 15-23 (1994) DOI ScienceOn |
10 | S.H. Lee, S.D. Yoo, and K.H. Lee, Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography, J. Chromatogr. B., 724, 357-363 (1999) DOI ScienceOn |
11 | R.T. Dorr, Pharmacology and toxicology of cremophor EL diluent, Ann. Pharmacothera., 28, S11-S17 (1994) DOI |
12 | S. Charman, W. Charman, M. Rogge, T. Wilson, F. Dutko and C. Pouton, Self-emulsifying drug delivery systems: formulation and biopharmaceutics evaluation of an investigations lipophilic compound, Pharm. Res., 9, 87-93 (1992) DOI |
13 | T. Cresteil, B. Monsarrat, P. Alvinerie, J.M. Treluyer, I. Vieira and M. Wright, Taxol metabolism by human liver microsomes : identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386-392 (1994) |
14 | G.A. Fisher and B.I. Sickic, Clinical studies with modulators of multidrug resistance, Hematol. Oncol. Clin. North Am., 9, 363-382 (1995) DOI |
15 | M. Martin, J. Catalin, M.F. Blachon and A. Durand, Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography, J. Chromatogr. B., 709, 281-288 (1998) DOI ScienceOn |
16 | S. Yang, R.N. Gursoy, G. Lambert and S. Benita, Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of Pglycoprotein inhibitors, Pharm. Res., 21, 261-270 (2004) DOI ScienceOn |
17 | J. Kovarik, E. Muelle, J. Van Bree, W. Tetzloff and K. Kutz, Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation, J. Pharm. Sci., 83, 444-446 (1994) DOI ScienceOn |
18 | J.A. Straub, D.E. Chickering, J.C. Lovely, H. Zhang, B. Shah, W.R. Waud and H. Bernstein, Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850), Pharm. Res., 22, 347-355 (2005) DOI |
19 | J.S. Choi, H.K. Choi and S.C. Shin, Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats, Int. J. Pharm., 275, 165-170 (2004) DOI ScienceOn |